|Bid||156.00 x 1000|
|Ask||156.10 x 800|
|Day's Range||154.00 - 157.56|
|52 Week Range||117.64 - 186.22|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||201.65|
Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed. Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) struggled to differentiate Sunosi in a generic market, and SVB remains skeptical that Axsome will be able to do much better. Related: Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.